Medical Licensing (MD/DO) · Independent exam preparation
ABIM Endocrinology, Diabetes, and Metabolism Certification: Clinical Decision Guide Study Guide
Practise endocrine diagnosis, test interpretation, and treatment decisions with 60 focused concepts, 20 clinical questions, and 20 active-recall flashcards.
By CertMedbry · Updated 18 October 2026
Distinguish hormone deficiency from resistance, interpret discordant laboratory results, and choose treatments that account for fertility, fracture risk, cardiovascular disease, and hypoglycemia. This selective guide develops selected clinical decisions across all eight domains. The [official expanded CERT outline](https://www.abim.org/media/1kwlvo2v/endocrinology-diabetes-metabolism.pdf) defines the full examination scope; these 60 concepts do not replace it.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide address?
This guide addresses the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Certification Examination for physician subspecialty certification. The examination does not confer a medical license. Eligibility is governed by ABIM's subspecialty certification policies.
ABIM Endocrinology, Diabetes, and Metabolism Certification Policies
Which blueprint version applies, and does it also describe MOC?
The official CERT blueprint has a January 2026 footer and is linked from ABIM's certification blueprint index. No separate effective date is stated. ABIM lists certification and Maintenance of Certification assessment blueprints separately; this guide uses the certification blueprint.
ABIM Blueprints · Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
How many questions are included, and which questions count toward the score?
The official blueprint describes up to 240 single-best-answer multiple-choice questions, including approximately 40 new questions that do not count toward the examinee's score. These qualified figures do not guarantee a fixed number of scored questions.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
What question styles and clinical materials should candidates expect?
Most questions describe patient scenarios involving diagnosis, test selection and interpretation, treatment, risk assessment, prognosis, epidemiology, or applied pathophysiology. Clinical materials may include diagnostic images, continuous glucose monitoring tracings, radiographs, and patient photographs. This guide's 20 four-option questions are independent single-best-answer drills.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
Where are subspecialty eligibility requirements established?
ABIM's Endocrinology, Diabetes, and Metabolism certification policies establish the subspecialty certification pathway. The policy page references the December 2025 Policies and Procedures for Certification as superseding earlier policy publications.
ABIM Endocrinology, Diabetes, and Metabolism Certification Policies
How is the examination content weighted?
The January 2026 blueprint assigns Adrenal Disorders 10%; Pituitary Disorders 10%; Lipids, Obesity, and Nutrition 12%; Female Reproduction 7%; Male Reproduction 7%; Diabetes Mellitus and Hypoglycemia 24%; Calcium and Bone Disorders 15%; and Thyroid Disorders 15%. The guide approximately follows these weights with 6, 6, 7, 4, 4, 15, 9, and 9 concepts, respectively. Each 20-item practice set uses small-set rounding across every domain.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
Do the 60 concepts cover the entire official outline?
No. They provide selective clinical teaching across every official domain. The expanded official outline remains the full scope, including less common disorders, endocrine imaging and procedures, reproductive care, pregnancy, complications, and clinically relevant health equity. Actual examination content may vary within that outline.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
The guide, questions, and flashcards are independently authored educational materials, not official ABIM examination items or an ABIM-endorsed product.
Outline used: January 2026 Certification Examination (CERT) blueprint, linked from ABIM's current official blueprint index and opened on 2026-10-09. The workbook label 'ABIM - Subspecialty in Endocrinology, Diabetes, and Metabolism' maps to this examination; the assigned slug is preserved. No separate effective date is stated in the blueprint.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Adrenal Disorders10%
1.Which findings distinguish primary from central adrenal insufficiency?
Primary adrenal insufficiency damages the adrenal cortex, reducing cortisol and often aldosterone. Loss of cortisol feedback raises ACTH; mineralocorticoid deficiency raises renin and can cause hyperkalemia and volume depletion. Central ACTH deficiency usually preserves aldosterone because the renin–angiotensin system remains functional. Hyperpigmentation and hyperkalemia therefore favor primary disease, while their absence does not exclude cortisol deficiency. Interpret cortisol together with ACTH and assess renin and aldosterone when primary disease is suspected.
Apply it
A patient with weight loss, orthostatic symptoms, sodium of 128 mmol/L, potassium of 5.8 mmol/L, and new mucosal pigmentation has a low morning cortisol. Measure ACTH and evaluate mineralocorticoid function rather than assuming isolated pituitary disease.
Common pitfall: Hyponatremia occurs in both primary and central cortisol deficiency. Using sodium alone to localize the disorder misses the more discriminating ACTH and mineralocorticoid findings.
2.When should suspected adrenal crisis be treated before confirmation?
Adrenal crisis is an emergency in which inadequate cortisol impairs vascular responsiveness and stress adaptation. Hypotension, gastrointestinal symptoms, volume depletion, hypoglycemia, or electrolyte abnormalities can support suspicion. If feasible, obtain cortisol and ACTH before treatment, but immediately provide parenteral hydrocortisone and fluid resuscitation when crisis is suspected. Treatment must not wait for stimulation testing. Search for the precipitating illness while monitoring circulation, glucose, and electrolytes.
Apply it
A patient with known autoimmune adrenal insufficiency develops vomiting and hypotension during gastroenteritis and cannot retain tablets. Give emergency parenteral glucocorticoid and intravenous fluids immediately, while assessing glucose and the infectious trigger.
Common pitfall: Waiting for a cortisol result or completing a cosyntropin test before treatment prolongs shock. A diagnostic blood sample is useful only when it causes no meaningful delay.
3.How does cosyntropin testing assess adrenal cortisol reserve?
Cosyntropin supplies an ACTH stimulus and measures the adrenal cortisol response. An inadequate stimulated response supports adrenal insufficiency, but the decision threshold depends on the cortisol assay and testing protocol. Pair the result with baseline ACTH to help localize disease. A stimulation result measures adrenal responsiveness rather than every aspect of hypothalamic–pituitary function, and recent central injury can precede loss of adrenal responsiveness. Clinical timing and glucocorticoid exposure therefore matter.
Apply it
A stable patient has fatigue and an indeterminate morning cortisol. Arrange a standardized corticotropin stimulation test, document recent steroid use, and interpret the measured peak using the laboratory's validated cortisol assay threshold.
Common pitfall: Applying one historical cortisol cutoff to every modern assay can misclassify patients. A stimulation test also does not independently distinguish primary disease from every central cause.
Primary Adrenal Insufficiency Guideline Resources · Hormone Replacement in Hypopituitarism Guideline Resources
4.How do potassium and medications alter primary aldosteronism screening?
Primary aldosteronism produces aldosterone that is inappropriate for a suppressed renin level. Screening interprets aldosterone, renin, and their ratio together rather than treating the ratio as an isolated diagnosis. Hypokalemia can suppress aldosterone and obscure disease. Beta blockers can suppress renin and inflate the ratio, whereas mineralocorticoid antagonists and other agents can change renin and aldosterone substantially. Correct potassium and use a safe, individualized medication strategy when interpreting or repeating testing.
Apply it
A hypertensive patient taking a beta blocker has a high aldosterone–renin ratio but a low aldosterone concentration. Review renin suppression and medication effects before declaring autonomous aldosterone production or ordering an adrenal operation.
Common pitfall: A large ratio caused by an extremely small denominator is not sufficient evidence of autonomous secretion. Conversely, hypokalemia can conceal a clinically important aldosterone excess.
5.Why is adrenal venous sampling often needed before adrenalectomy?
Adrenal computed tomography shows anatomy but cannot reliably establish which adrenal gland is producing excess aldosterone. A visible nodule may be nonfunctioning, and the opposite gland may be the source or both glands may contribute. In patients with primary aldosteronism who are considering surgery, adrenal venous sampling generally establishes lateralization alongside imaging. The result separates potentially surgically treatable unilateral secretion from bilateral disease, for which mineralocorticoid receptor blockade is usually the targeted treatment.
Apply it
A 58-year-old surgical candidate with confirmed primary aldosteronism has a left adrenal nodule. Discuss adrenal venous sampling before choosing left adrenalectomy because the nodule's location does not establish the source of secretion.
Common pitfall: Operating solely on the larger adrenal nodule confuses structural and functional evidence. Selected exceptions to sampling should not become a general rule for all surgical candidates.
6.How should suspected Cushing syndrome be tested before its source is localized?
Progressive findings such as proximal weakness, easy bruising, and violaceous striae increase suspicion beyond isolated obesity or hypertension. First review all routes of exogenous glucocorticoid exposure. Initial testing can use two late-night salivary cortisol samples, at least two 24-hour urinary free cortisol measurements, or a 1-mg overnight dexamethasone suppression test. An abnormal initial result generally requires another recommended test and assessment of confounders. After endogenous hypercortisolism is established, ACTH helps distinguish adrenal autonomous secretion from ACTH-dependent disease.
Apply it
A patient develops progressive bruising, muscle weakness, and worsening diabetes. Review steroid exposure and perform an appropriate cortisol screening test before ordering pituitary or adrenal imaging.
Common pitfall: Random cortisol and ACTH are unsuitable screening tests. An incidental pituitary or adrenal lesion cannot establish Cushing syndrome without biochemical evidence.
Diagnosis of Cushing’s Syndrome Guideline Resources | Endocrine Society
Pituitary Disorders10%
7.How is central hypothyroidism recognized and safely replaced?
Central hypothyroidism reflects inadequate hypothalamic or pituitary stimulation. Low free T4 with low, normal, or mildly elevated TSH supports the diagnosis in an appropriate pituitary context because measured TSH may be biologically inadequate. Evaluate cortisol reserve before levothyroxine: thyroid replacement increases metabolic requirements and cortisol clearance and can precipitate adrenal decompensation. Treat established cortisol deficiency first; provide glucocorticoid coverage if plausible deficiency cannot promptly be excluded. Adjust levothyroxine using free T4, generally targeting the mid to upper reference range while considering age and clinical circumstances.
Apply it
After treatment of a pituitary mass, a patient has low free T4, normal TSH, and very low morning cortisol. Begin glucocorticoid replacement before levothyroxine and subsequently monitor thyroid replacement with free T4.
Common pitfall: Normal TSH excludes neither central hypothyroidism nor inadequate replacement. Treating thyroid deficiency before assessing the adrenal axis can destabilize a patient with combined deficiencies.
8.How should hyperprolactinemia be evaluated before diagnosing a prolactinoma?
Assess pregnancy, medication effects, hypothyroidism, renal dysfunction, and pituitary or stalk disease. Repeat an uncertain mild elevation without excessive sampling stress. In an asymptomatic patient, assess macroprolactin, which can raise measured prolactin without comparable biological activity. A very large pituitary mass with only modest prolactin elevation requires sample dilution to exclude the hook effect, in which antigen excess produces a falsely low result. Persistent unexplained hyperprolactinemia warrants pituitary assessment. Cabergoline is preferred dopamine-agonist therapy for symptomatic prolactinomas to lower prolactin and shrink the tumor. [Endocrine Society hyperprolactinemia guideline](https://academic.oup.com/jcem/article/96/2/273/2709487).
Apply it
A patient has a large sellar mass and mildly elevated prolactin. Request dilution testing before classifying the lesion as nonfunctioning with stalk-related prolactin elevation.
Common pitfall: A raised prolactin does not automatically identify a prolactinoma. Coordinate any change to an implicated psychiatric medication with its prescriber.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
9.When can IGF-1 confirm acromegaly, and when is additional testing useful?
GH secretion is pulsatile, whereas IGF-1 provides a more integrated measure of GH action. Under the current acromegaly consensus, characteristic clinical features together with IGF-1 above 1.3 times the age-adjusted upper limit of normal can confirm acromegaly; mandatory glucose-suppression testing is unnecessary in that clear presentation. For equivocal results, repeat IGF-1 using the same validated assay and consider oral glucose testing with GH measurements. Older Endocrine Society guidance emphasized confirming elevated IGF-1 through failure of GH suppression during oral glucose testing. Interpret assay results and possible confounders in clinical context.
Apply it
An adult with progressive acral enlargement and typical facial changes has IGF-1 at 1.8 times the age-adjusted upper limit. Recognize that this can establish the diagnosis and proceed to pituitary imaging and assessment of complications.
Common pitfall: Neither a pituitary lesion alone nor one random GH concentration establishes or excludes acromegaly. Borderline IGF-1 without characteristic features requires a different approach from a clear clinical and biochemical presentation.
Consensus on criteria for acromegaly diagnosis and remission - PMC · Acromegaly — Endocrine Society Guideline Resources
10.How do paired blood and urine findings clarify polyuria?
First establish true polyuria and distinguish water diuresis from solute diuresis. Hyperglycemia can drive osmotic urine losses, whereas arginine vasopressin deficiency or resistance produces urine that is inappropriately dilute relative to plasma. Interpret urine osmolality with serum sodium, plasma osmolality, glucose, fluid intake, and medication exposure. Primary polydipsia can also produce dilute urine, so urine dilution alone is insufficient. Specialist dynamic testing may be needed after this initial physiological classification.
Apply it
Following pituitary surgery, a patient develops large urine volumes, rising serum sodium, normal glucose, and very dilute urine. Evaluate water diuresis and possible vasopressin deficiency rather than attributing the output to uncontrolled diabetes mellitus.
Common pitfall: Urinary frequency is not necessarily polyuria. Dilute urine in someone drinking excessive water also does not independently establish vasopressin deficiency or justify automatic desmopressin treatment.
11.Which morning cortisol results guide evaluation of central adrenal insufficiency?
For suspected central adrenal insufficiency, an 8–9 AM cortisol is the initial biochemical assessment rather than a random measurement. The hypopituitarism guideline considers a value below 3 micrograms/dL indicative of adrenal insufficiency and a value above 15 micrograms/dL likely to exclude it; intermediate results generally require stimulation testing. Interpret these thresholds with assay characteristics, illness, binding-protein effects, and glucocorticoid exposure. Recent pituitary injury can complicate interpretation of adrenal responsiveness.
Apply it
A stable patient with pituitary disease has an 8 AM cortisol of 7 micrograms/dL and no recent glucocorticoid exposure. Arrange further adrenal testing rather than diagnosing normal reserve from that intermediate value.
Common pitfall: A cortisol collected late in the day cannot be substituted directly into morning thresholds. Recent exogenous glucocorticoids can also invalidate an otherwise straightforward interpretation.
12.Why can desmopressin treatment cause hyponatremia?
Desmopressin replaces the antidiuretic effect missing in central vasopressin deficiency. While active, it limits renal free-water excretion, so continued excessive drinking can cause water retention and dilutional hyponatremia. Treatment requires individualized timing, education about fluid intake, and sodium monitoring when clinically indicated. Assess symptoms and the pattern of breakthrough urine output rather than simply eliminating every episode of urination. Changes in thirst, illness, and other hormone replacement can alter water balance.
Apply it
A patient receiving desmopressin develops headache and low sodium after deliberately increasing water intake. Review medication timing, fluid intake, and serum sodium promptly rather than increasing desmopressin because the original diagnosis involved polyuria.
Common pitfall: Treating thirst or habitual drinking as proof of inadequate desmopressin can worsen water intoxication. Low sodium during treatment requires reassessment of water balance and exposure.
Lipids, Obesity, and Nutrition12%
13.Why should hypothyroidism be considered before labeling dyslipidemia primary?
Thyroid hormone deficiency can raise LDL cholesterol and triglycerides by altering lipid metabolism and clearance. The lipid guideline recommends ruling out hypothyroidism as a cause of hyperlipidemia and reassessing the lipid profile after thyroid hormone levels normalize. This identifies a reversible contributor and improves interpretation of residual cardiovascular risk. A secondary cause and inherited dyslipidemia can coexist, so correction of thyroid dysfunction does not guarantee that all lipid abnormalities will disappear.
Apply it
A patient with newly elevated LDL cholesterol also reports cold intolerance and constipation. Check thyroid function, treat confirmed overt hypothyroidism, and reassess the lipid profile before deciding how much persistent dyslipidemia requires separate treatment.
Common pitfall: Assuming every marked LDL elevation is familial ignores reversible endocrine disease. Conversely, normalizing thyroid function does not remove the need to reassess cardiovascular risk.
14.When do triglycerides require a pancreatitis-prevention strategy?
Severe hypertriglyceridemia creates a treatment goal beyond long-term atherosclerotic risk reduction: preventing pancreatitis. The Endocrine Society recommends pharmacological treatment as an adjunct to diet and exercise when fasting triglycerides exceed 500 mg/dL. At levels above 1,000 mg/dL, medication alone may be inadequate, making dietary modification, weight management, and diabetes control particularly important. Evaluate alcohol exposure, medications, endocrine disease, and other secondary contributors while choosing triglyceride-directed therapy.
Apply it
A patient has fasting triglycerides of 1,450 mg/dL, heavy alcohol intake, and uncontrolled diabetes. Address all three drivers with a pancreatitis-prevention plan rather than focusing only on the calculated LDL cholesterol value.
Common pitfall: A statin-centered cardiovascular plan alone may leave severe triglyceride elevation insufficiently addressed. Medication also cannot reliably compensate for persistent major dietary and metabolic contributors.
15.How should modest glycemic worsening affect an indicated statin?
Statins can modestly increase glucose or diabetes risk, but this effect must be weighed against their reduction in atherosclerotic cardiovascular events. The lipid guideline advises continuing indicated statin therapy rather than stopping it solely because diabetes develops or glycemic control worsens. Reassess lifestyle, glucose management, and the patient's overall cardiovascular risk. The relevant decision compares clinical benefits and harms, rather than treating every adverse laboratory change as a reason to abandon effective prevention.
Apply it
A patient with established atherosclerotic disease develops a small A1C increase after starting a statin. Continue indicated lipid therapy and address glycemia rather than withdrawing cardiovascular protection because of the isolated laboratory change.
Common pitfall: Equating a modest rise in glucose with net cardiovascular harm overlooks treatment benefit. The appropriate response is usually glucose assessment and management alongside continued indicated statin therapy.
16.Why does obesity treatment retain nutrition, activity, and behavioral support?
Obesity treatment addresses a chronic condition influenced by appetite regulation, environment, behavior, and comorbid disease. Nutrition, physical activity, and behavioral support remain foundational even when medication or procedural treatment is added. These measures support health, function, and maintenance rather than serving only as a preliminary test of motivation. Assess barriers, eating patterns, medication contributors, sleep, and patient priorities to create a feasible plan. Treatment intensity should reflect health burden and response.
Apply it
A patient starting obesity medication works rotating shifts and lacks regular meal access. Build practical meal planning, activity, and follow-up around those constraints so the treatment plan remains achievable alongside pharmacological appetite management.
Common pitfall: Prescribing medication without addressing access and daily routines can undermine adherence. Lifestyle counseling should identify workable changes rather than attribute obesity to inadequate willpower.
17.When can anti-obesity medication supplement lifestyle treatment?
The Endocrine Society framework supports adding pharmacotherapy to lifestyle treatment for adults with BMI at least 30 kg/m², or at least 27 kg/m² with an associated comorbidity. Eligibility does not by itself choose a drug: contraindications, other medications, reproductive plans, adverse effects, and treatment goals remain central. Product-specific indications and current prescribing information govern the selected agent. Assess response and tolerability over time because obesity generally requires continuing management.
Apply it
An adult has BMI 28 kg/m², hypertension, and insufficient improvement with structured lifestyle treatment. Discuss medication eligibility and individual contraindications rather than denying treatment solely because BMI is below 30 kg/m².
Common pitfall: BMI thresholds identify a treatment framework rather than an automatic prescription. The presence of a qualifying BMI does not override pregnancy considerations, contraindications, or product-specific requirements.
18.How should response guide continued obesity pharmacotherapy?
Obesity medication should be continued when it produces meaningful benefit and remains safe, with monitoring of weight, comorbidities, and adverse effects. The guideline's general benchmark is at least 5% weight loss after three months for an effective, tolerated treatment; individual products have their own titration and stopping rules. An inadequate response should prompt reassessment of adherence, dose, tolerability, and alternative treatment. Do not apply a single calendar rule without considering the specific agent.
Apply it
A patient taking a weight-management medication has little benefit and troublesome adverse effects after an adequate therapeutic trial. Review the product's response criteria and discuss discontinuation or a different strategy rather than continuing indefinitely.
Common pitfall: Applying an older general stopping threshold to every newer medication and titration schedule can misclassify response. Product-specific treatment exposure and clinical benefit must inform reassessment.
19.Which secondary contributors should be sought in mixed dyslipidemia?
Elevated LDL cholesterol and triglycerides may reflect several interacting processes rather than a single inherited disorder. Evaluate glycemic control, thyroid function, alcohol intake, kidney disease, nutrition, and medication exposure. Identify whether the immediate concern is severe triglyceride-related pancreatitis risk, long-term atherosclerotic risk, or both. Correcting secondary drivers can substantially change the lipid pattern, but residual abnormalities still require risk-based treatment. Use repeat measurements after meaningful clinical changes to reassess the phenotype.
Apply it
A patient develops higher triglycerides after worsening diabetes and increased alcohol intake, with persistently elevated LDL cholesterol. Treat the secondary drivers while separately assessing pancreatitis risk and the indication for LDL-lowering therapy.
Common pitfall: Naming a primary lipid phenotype before reviewing secondary factors can lead to unnecessary diagnostic certainty. Treating one component also does not automatically control the other lipid-related risks.
Female Reproduction7%
20.Which adult findings establish polycystic ovary syndrome?
In adults, PCOS diagnosis generally requires two of three features after excluding alternative causes: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. The 2023 guideline permits appropriately used anti-Müllerian hormone assessment as an alternative to ultrasound for defining ovarian morphology in adults. When irregular cycles and hyperandrogenism are already present, ultrasound is not required. Adolescent diagnosis is different and should not borrow adult imaging or AMH criteria indiscriminately.
Apply it
An adult has persistent irregular cycles and hirsutism. After excluding pregnancy and relevant endocrine mimics, recognize that these findings can establish PCOS without requiring an ultrasound merely to obtain a third diagnostic feature.
Common pitfall: Polycystic-appearing ovaries alone do not diagnose PCOS. Adult ultrasound and AMH approaches also should not be transferred automatically to adolescents with evolving menstrual physiology.
Recommendations from the 2023 International Evidence-based Guideline for Polycystic Ovary Syndrome
21.Which ovulation-induction treatment is preferred for uncomplicated PCOS-related anovulatory infertility?
For anovulatory infertility in PCOS without other infertility factors, the 2023 international guideline recommends letrozole as first-line pharmacological ovulation induction. Aromatase inhibition reduces estrogen feedback and promotes endogenous gonadotropin stimulation. Confirm the reproductive goal, exclude existing pregnancy, and evaluate other infertility factors as appropriate. Menstrual regulation with contraception serves a different purpose, and insulin-sensitizing therapy is not automatically the most effective first ovulation-induction choice.
Apply it
A patient with PCOS has anovulatory infertility, a reassuring partner evaluation, and no identified additional infertility factor. Discuss letrozole-based induction after excluding pregnancy rather than selecting medication solely to make withdrawal bleeding predictable.
Common pitfall: Regular withdrawal bleeding on hormonal contraception does not demonstrate ovulation or treat infertility. A PCOS diagnosis also does not eliminate possible partner or tubal factors.
Recommendations from the 2023 International Evidence-based Guideline for Polycystic Ovary Syndrome
22.How does low energy availability cause functional hypothalamic amenorrhea?
Insufficient energy availability, psychological stress, and excessive exercise can suppress hypothalamic reproductive signaling, reducing gonadotropin stimulation and ovarian estrogen production. Functional hypothalamic amenorrhea is a diagnosis of exclusion, beginning with pregnancy exclusion and assessment for other causes. Treatment prioritizes correcting the energy imbalance through improved nutrition, reduced excessive exercise when appropriate, and psychological support. Menstrual suppression can occur without a markedly low BMI, so weight alone cannot exclude the condition.
Apply it
A recreational athlete develops amenorrhea after increasing training and restricting food, despite a BMI in the reference range. Exclude pregnancy and other endocrine causes, then address energy availability rather than assuming normal BMI rules out hypothalamic suppression.
Common pitfall: Using BMI as the sole nutritional screen misses energy deficiency. Labeling exercise-associated amenorrhea physiological also overlooks reproductive and skeletal consequences that require active assessment.
23.How do initial tests distinguish ovarian from central causes of amenorrhea?
Exclude pregnancy first. History, examination, TSH, prolactin, FSH, and estradiol identify common endocrine causes. Low estradiol with elevated FSH favors ovarian insufficiency; low estradiol with low or inappropriately normal gonadotropins favors hypothalamic or pituitary dysfunction. In someone younger than 40, an ovarian failure pattern warrants assessment for primary ovarian insufficiency rather than attribution to ordinary menopause. For primary amenorrhea, breast development and the presence of a uterus help direct evaluation toward estrogen deficiency, anatomic abnormalities, or disorders of sexual development.
Apply it
A 32-year-old with amenorrhea and hot flashes has low estradiol and markedly elevated FSH. Evaluate ovarian insufficiency rather than assuming exercise-related hypothalamic suppression.
Common pitfall: A low estradiol concentration alone does not localize the disorder. Interpreting FSH without the estrogen level, reproductive history, and medication exposure can misclassify the cause.
Male Reproduction7%
24.How is testosterone deficiency confirmed before treatment?
Diagnose male hypogonadism when compatible symptoms or signs coexist with unequivocally and consistently low testosterone. Confirm an initial low result with a repeat morning fasting total testosterone measurement using an accurate assay. Assess free testosterone when total testosterone is near the lower limit or altered sex hormone-binding globulin makes interpretation unreliable. Acute illness and reversible contributors can suppress levels. Before treatment, assess fertility plans, hematocrit, untreated severe sleep apnea, and relevant prostate or breast findings; subsequently monitor symptoms, testosterone, hematocrit, and prostate risk when indicated.
Apply it
A man with nonspecific fatigue has one low afternoon testosterone level during an acute illness. Repeat testing under appropriate morning fasting conditions after recovery and assess relevant symptoms before diagnosing hypogonadism or prescribing testosterone.
Common pitfall: One low measurement or fatigue alone is insufficient. Monitoring only testosterone also misses treatment-related erythrocytosis and other clinically important harms.
25.How do LH and FSH localize confirmed male hypogonadism?
After confirming testosterone deficiency, LH and FSH help distinguish testicular from hypothalamic–pituitary disease. Elevated gonadotropins indicate inadequate gonadal response and favor primary hypogonadism. Low or inappropriately normal gonadotropins suggest secondary hypogonadism. That distinction directs evaluation toward testicular causes or central and functional contributors, including pituitary disease, medication effects, and systemic illness. A gonadotropin result must be interpreted relative to the low testosterone rather than against its reference interval alone.
Apply it
A man has repeatedly low morning testosterone with LH that remains low-normal. Recognize inadequate pituitary stimulation and investigate central or reversible functional causes instead of assuming a normal LH concentration excludes endocrine disease.
Common pitfall: A laboratory value within range can still be physiologically inappropriate. Normal-range LH should rise when testosterone is low if pituitary feedback responses are intact.
26.How should male infertility assessment extend beyond a serum testosterone measurement?
Begin with reproductive and medication history, examination, and semen analysis, evaluating both partners in parallel. Obtain FSH and testosterone when findings such as oligozoospermia, azoospermia, small testes, or endocrine symptoms suggest hormonal dysfunction. Azoospermia with small testes and elevated FSH favors impaired sperm production; obstruction is assessed using semen characteristics, examination, and hormonal findings together. Exogenous testosterone suppresses LH, FSH, and intratesticular testosterone, so it can reduce spermatogenesis despite improving serum androgen levels. Avoid routine testosterone initiation when near-term fertility is desired.
Apply it
A man seeking conception has azoospermia and small testes. Assess sperm-production failure and gonadotropins rather than prescribing testosterone as an empirical fertility treatment.
Common pitfall: Normal serum testosterone does not establish normal sperm production. A normal FSH concentration also does not independently prove an obstructive cause of azoospermia.
Testosterone Therapy for Hypogonadism Guideline Resources · Male%20Infertility%20Unabridged%20Final.pdf
27.How should gynecomastia be distinguished from adiposity and a suspicious breast mass?
True gynecomastia contains palpable glandular tissue, usually centered beneath the areola; lipomastia is predominantly fat without glandular proliferation. A hard mass outside the areola, nipple retraction or bleeding, skin changes, or axillary nodes raises concern for malignancy and warrants tissue evaluation. Review medications, androgen exposure, onset, sexual function, and systemic illness. Examine the testes and assess testosterone, estradiol, gonadotropins, hCG, thyroid function, and liver or renal function as appropriate; testicular ultrasound can detect nonpalpable tumors. Treat the cause and reassess after withdrawal of implicated substances when feasible. [EAA gynecomastia guideline](https://onlinelibrary.wiley.com/doi/10.1111/andr.12636).
Apply it
An adult with new breast enlargement has a hard unilateral mass lateral to the nipple and nipple retraction. Pursue malignancy assessment rather than treating presumed benign gynecomastia.
Common pitfall: A plausible medication contributor does not exclude another cause. Testosterone is appropriate only for proven deficiency and can worsen gynecomastia in eugonadal men through aromatization.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
Diabetes Mellitus and Hypoglycemia24%
28.Which laboratory thresholds diagnose diabetes outside pregnancy?
Diabetes can be diagnosed by A1C at least 6.5%, fasting plasma glucose at least 126 mg/dL after an adequate fast, or two-hour plasma glucose at least 200 mg/dL during a 75-g oral glucose tolerance test. Random plasma glucose at least 200 mg/dL is diagnostic with classic hyperglycemic symptoms or hyperglycemic crisis. Without unequivocal hyperglycemia, confirmation is required. These are laboratory diagnostic criteria; home meter or sensor readings are not interchangeable substitutes.
Apply it
An asymptomatic adult has fasting plasma glucose of 132 mg/dL during routine screening. Obtain confirmatory diagnostic testing rather than dismissing the result as prediabetes or declaring diabetes from one unconfirmed abnormal value.
Common pitfall: The random glucose threshold requires the appropriate symptomatic or crisis context. A single abnormal screening result in an asymptomatic person ordinarily requires confirmation.
Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
29.How should discordant diabetes diagnostic tests be resolved?
Different diagnostic tests measure different aspects of glycemia, so their results can disagree. If two tests are discordant, repeat the test that exceeds its diagnostic threshold while considering factors that could distort either measurement. Diabetes is established by confirmation of the abnormal result, rather than requiring every available test to cross its threshold. Marked discordance should also prompt examination of A1C reliability, sample handling, recent illness, and the timing of glucose exposure.
Apply it
An asymptomatic adult has A1C of 6.8% and fasting plasma glucose of 118 mg/dL, with no evident A1C interference. Repeat the A1C to assess confirmation instead of averaging the tests into a prediabetes classification.
Common pitfall: Requiring both A1C and fasting glucose to be diagnostic can miss diabetes. Conversely, unexplained discordance should not be ignored when a measurement may be unreliable.
Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
30.Why can A1C misrepresent glycemia when red-cell turnover changes?
A1C reflects glucose exposure over the lifespan of circulating erythrocytes. Conditions that shorten red-cell survival, such as hemolysis, can lower A1C relative to actual glycemia; transfusion and other changes in erythrocyte populations can also disrupt interpretation. Some hemoglobin variants affect particular assays. When the relationship between A1C and glycemia is altered, use plasma glucose criteria for diagnosis. A reassuring A1C should not override strong biochemical evidence of hyperglycemia.
Apply it
A patient with active hemolysis has repeatedly high laboratory glucose but an unexpectedly low A1C. Base diagnostic assessment on plasma glucose and investigate the discordance rather than concluding that average glycemia must be normal.
Common pitfall: Treating A1C as a direct glucose measurement overlooks erythrocyte biology. Changing the diagnostic label without considering red-cell survival can delay recognition of diabetes.
Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
31.When should adult-onset diabetes raise concern for autoimmune insulin deficiency?
Type 1 diabetes can begin in adulthood and progress at variable rates. Unintentional weight loss, ketosis, marked hyperglycemia, autoimmune history, or rapid failure of noninsulin treatment should raise concern for autoimmune beta-cell loss. Islet autoantibodies support classification, while C-peptide can help characterize endogenous insulin secretion in the appropriate setting. Age and body size alone cannot establish diabetes type. Recognizing insulin deficiency matters because delayed insulin treatment can permit metabolic decompensation.
Apply it
An adult initially labeled as having type 2 diabetes loses weight and rapidly deteriorates despite oral medication. Evaluate for autoimmune diabetes and insulin deficiency rather than escalating noninsulin treatment solely because the diagnosis occurred in adulthood.
Common pitfall: Obesity does not exclude autoimmune diabetes, and adult onset does not prove type 2 disease. Classification should follow the clinical course and supporting biochemical evidence.
Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
32.Which retinal findings change diabetes complication management?
Screen adults with type 2 diabetes at diagnosis and adults with type 1 diabetes after five years. Retinal neovascularization indicates proliferative disease, whereas macular edema can occur at other stages of retinopathy. Either finding requires prompt ophthalmic referral. Center-involving macular edema with impaired vision usually receives intravitreal anti-VEGF therapy. Distinguish retinopathy stage from macular involvement because they identify different treatment needs. [ADA 2026 retinopathy recommendations](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690177/).
Apply it
Retinal neovascularization needs treatment assessment even with preserved acuity; center-involving edema can require treatment without proliferative disease.
Common pitfall: Absence of visual symptoms does not exclude sight-threatening disease.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
33.How are gestational diabetes and postpartum dysglycemia diagnosed?
Early pregnancy testing can identify previously unrecognized diabetes using standard diagnostic criteria. Do not apply later-pregnancy gestational diabetes thresholds to early screening. At 24–28 weeks, the one-step fasting 75-g OGTT diagnoses GDM when any value reaches fasting 92, one-hour 180, or two-hour 153 mg/dL. An accepted alternative is two-step testing with a nonfasting 50-g screen followed, when positive, by a fasting 100-g OGTT. After GDM, perform a 75-g OGTT at 4–12 weeks postpartum using nonpregnant criteria, then screen every 1–3 years.
Apply it
At 26 weeks, a 75-g OGTT gives fasting 94, one-hour 172, and two-hour 142 mg/dL. The fasting result alone establishes GDM under the one-step approach; arrange postpartum testing even if glucose normalizes after delivery.
Common pitfall: Requiring two abnormal values incorrectly imports a feature of the two-step diagnostic pathway into the one-step test. A normal postpartum test does not eliminate future diabetes risk.
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 - PMC
34.Why can an SGLT2 inhibitor be useful beyond glucose lowering?
SGLT2 inhibitors reduce renal glucose reabsorption, increasing urinary glucose excretion. Selected agents also reduce important heart failure and chronic kidney disease outcomes in appropriate patients, making comorbid disease relevant to selection. These benefits do not remove treatment cautions: genital infections, volume depletion, and ketoacidosis risk require attention. Ketoacidosis may occur without extreme hyperglycemia. Match the specific agent and indication to kidney function, clinical context, and patient education rather than treating the class as interchangeable.
Apply it
A patient with type 2 diabetes and heart failure needs treatment review despite an A1C near the individualized goal. Consider an agent with demonstrated heart failure benefit while discussing hydration, genital symptoms, and ketoacidosis warning signs.
Common pitfall: Selecting medication solely by the current A1C can miss cardiorenal benefit. Conversely, modest glucose readings do not exclude ketoacidosis in an unwell SGLT2 inhibitor user.
What Are My Options for Type 2 Diabetes Medications? — ADA · 204629s040lbl.pdf
35.How does examination identify a diabetic foot at risk for ulceration?
At least annually, inspect skin and deformities, assess pulses, and test protective sensation with a 10-g monofilament plus another sensory assessment. Sensory loss or previous ulceration warrants inspection at every visit. Sensory testing does not replace skin or perfusion assessment. An ulcer requires coordinated evaluation of pressure, perfusion, and infection. [ADA 2026 foot-care recommendations](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690177/).
Apply it
An insensate plantar ulcer needs off-loading and assessment for ischemia and infection despite absent pain.
Common pitfall: Painlessness does not establish that an ulcer is superficial or uninfected; glucose control alone does not address its immediate causes.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
36.How should kidney disease be detected and treated in diabetes?
Assess both urine albumin-to-creatinine ratio and eGFR at least annually in all people with type 2 diabetes and in type 1 diabetes after five years. These measurements capture different dimensions of kidney injury; preserved filtration does not exclude albuminuric disease. In nonpregnant patients with diabetes, hypertension, and UACR of 30–299 mg/g, an ACE inhibitor or ARB is recommended; support is stronger with UACR at least 300 mg/g or eGFR below 60 mL/min/1.73 m². Monitor potassium and kidney function during treatment.
Apply it
A hypertensive patient with type 2 diabetes has eGFR 82 mL/min/1.73 m² and persistent UACR 180 mg/g. Recognize albuminuric kidney disease and assess renin–angiotensin system blockade despite preserved filtration.
Common pitfall: A normal serum creatinine does not exclude diabetic kidney disease. An isolated albumin elevation also requires assessment for transient contributors and persistence.
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 - PMC
37.When is glucagon needed for outpatient hypoglycemia rescue?
Severe hypoglycemia can impair a person's ability to swallow safely or self-treat. Glucagon provides rescue when oral carbohydrate is unsafe or impossible, and people at risk need an accessible prescription plus caregiver education. The hypoglycemia guideline favors preparations that do not require reconstitution over those that do. Rescue planning includes recognizing an emergency, knowing device use, and obtaining further help when needed. Following recovery, identify the event's cause and reduce recurrence risk.
Apply it
A partner finds an insulin-treated patient confused and unable to swallow safely. Use the available ready-to-use glucagon and seek emergency assistance rather than forcing juice into the patient's mouth or leaving to obtain food.
Common pitfall: Prescribing glucagon without teaching likely rescuers how to use it leaves a practical gap. Oral intake is unsafe when consciousness or swallowing is impaired.
38.How should recurrent hypoglycemia change a diabetes care plan?
Recurrent hypoglycemia signals a mismatch among treatment, food intake, activity, physiology, or monitoring. Review timing, insulin or secretagogue exposure, kidney function, awareness of warning symptoms, and practical barriers. Sulfonylureas can sustain insulin release despite missed meals, making reduced intake especially relevant. Structured education and appropriate continuous glucose monitoring can improve detection and prevention in high-risk patients. The response should reduce future exposure to low glucose rather than merely document a favorable A1C. Individualized treatment goals must account for severe episodes and impaired awareness.
Apply it
An insulin-treated patient has a low A1C but recurrent overnight lows and little warning. Review basal insulin, monitoring, and safety goals, and offer structured hypoglycemia education rather than praising the A1C as sufficient evidence of good control.
Common pitfall: A low A1C can conceal dangerous variability. Simply instructing the patient to eat more does not replace investigation of the regimen and impaired hypoglycemia awareness.
High Risk for Hypoglycemia Guideline Resources · What Are My Options for Type 2 Diabetes Medications? — ADA
39.Which hospitalized patients can continue using an insulin pump?
Selected noncritically ill patients can continue personal pump therapy when they can manage the device and the hospital has appropriate expertise, policies, and supplies. Impaired consciousness, inability to adjust settings, critical illness, diabetic ketoacidosis, or hyperosmolar crisis makes continued self-managed pump use inappropriate. If stopping a pump, arrange a planned transition to alternative insulin because pump users may lack a long-acting insulin depot. Eligibility must be reassessed when clinical status changes.
Apply it
A knowledgeable pump user admitted for an uncomplicated infection remains alert and has supplies in a hospital with pump expertise. Continuation may be reasonable, but new delirium would require reassessment and a coordinated insulin transition.
Common pitfall: Hospital admission alone does not mandate pump removal, but patient familiarity alone does not ensure safety. Stopping insulin delivery without replacement can create rapid insulin deficiency.
40.How should scheduled insulin address persistent or glucocorticoid-associated inpatient hyperglycemia?
Glucocorticoids increase insulin resistance and produce glucose patterns linked to steroid timing and duration. For noncritical inpatients, an NPH-based or basal–bolus regimen can be matched to steroid exposure and nutrition. In selected patients initially treated with correction insulin alone, at least two glucose readings of 180 mg/dL or higher within 24 hours support adding scheduled insulin. Reassess doses as illness, intake, and steroid exposure change. Steroid tapering can rapidly reduce insulin requirements and make an unchanged regimen cause hypoglycemia.
Apply it
Morning prednisone causes afternoon hyperglycemia despite acceptable fasting values. Match scheduled insulin to that pattern and reduce it as appropriate during tapering rather than repeatedly correcting isolated elevations.
Common pitfall: Fasting glucose alone can miss steroid-related hyperglycemia. Correction insulin treats an existing elevation but does not reliably prevent recurring hyperglycemia.
41.How should hypoglycemia independent of diabetes be confirmed and investigated?
Document Whipple's triad: compatible symptoms, low laboratory plasma glucose, and improvement when glucose rises. Review drugs, critical illness, hormone deficiency, and non-islet-cell tumors. During an unexplained episode, obtain glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and a sulfonylurea/meglitinide screen; also assess insulin antibodies. Inappropriately preserved insulin with C-peptide and suppressed ketogenesis suggests endogenous insulin secretion or a secretagogue; high insulin with suppressed C-peptide suggests exogenous insulin. If no spontaneous episode is captured, use a supervised fast for fasting symptoms or a mixed-meal test for postprandial symptoms. Establish the biochemical mechanism before pancreatic localization. [Endocrine Society adult hypoglycemia guideline](https://academic.oup.com/jcem/article/94/3/709/2596247).
Apply it
Recurrent fasting confusion resolves with glucose. Collect the critical biochemical sample during hypoglycemia and exclude secretagogues before attributing endogenous hyperinsulinism to an insulinoma.
Common pitfall: A low sensor reading alone does not establish Whipple's triad. Insulin must be judged relative to the concurrent low glucose, not its ordinary reference range.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
42.When should a familial diabetes pattern prompt consideration of monogenic disease?
Monogenic diabetes should be considered when the presentation does not fit common type 1 or type 2 patterns, especially with young onset, diabetes across successive generations, absent islet autoimmunity, or stable mild hyperglycemia. No single feature establishes the diagnosis. Genetic confirmation can change treatment, prognosis, and family counseling, so distinguishing these conditions from presumed type 1 or type 2 diabetes has practical value. Interpret family history alongside the clinical and biochemical phenotype.
Apply it
A lean young adult has persistent mild hyperglycemia, negative islet antibodies, and similarly affected relatives in three generations. Consider genetic evaluation rather than assuming that every familial cluster necessarily represents conventional type 2 diabetes.
Common pitfall: Family history alone is insufficient because type 2 diabetes is also strongly familial. Genetic testing should address a coherent phenotype rather than substitute for clinical classification.
Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
Calcium and Bone Disorders15%
43.How does PTH divide the differential diagnosis of hypercalcemia?
Elevated calcium should normally suppress parathyroid hormone. A high or inappropriately normal PTH therefore suggests a PTH-dependent process, including primary hyperparathyroidism or familial hypocalciuric hypercalcemia. Suppressed PTH directs evaluation toward non-PTH-mediated causes. Confirm the calcium abnormality with appropriate albumin interpretation or ionized calcium and assess repeated results in context. The physiological appropriateness of PTH matters more than whether the reported value falls inside the laboratory reference interval.
Apply it
A patient has repeatedly elevated calcium and PTH in the middle of its reference range. Recognize that PTH is not appropriately suppressed and evaluate PTH-dependent hypercalcemia instead of calling parathyroid function normal.
Common pitfall: Reference-range PTH is not necessarily normal physiology during hypercalcemia. Starting with localization imaging before establishing the biochemical category can send the evaluation in the wrong direction.
Evaluation and Management of Primary Hyperparathyroidism: Fifth International Workshop, 2022
44.How does urinary calcium help distinguish FHH from primary hyperparathyroidism?
The calcium-to-creatinine clearance ratio is urine calcium multiplied by serum creatinine, divided by serum calcium multiplied by urine creatinine, using compatible units. A ratio below 0.01 favors familial hypocalciuric hypercalcemia, but substantial overlap exists with primary hyperparathyroidism. Vitamin D deficiency, kidney dysfunction, low calcium intake, and thiazides can reduce urinary calcium. Integrate the ratio with calcium history, family history, medication exposure, and genetic assessment when appropriate before recommending surgery.
Apply it
Urine calcium is 4 mg/dL, urine creatinine 100 mg/dL, serum calcium 11 mg/dL, and serum creatinine 1 mg/dL. The ratio is 4/(11 × 100), approximately 0.00364; investigate FHH and confounders before surgery.
Common pitfall: A low clearance ratio is a clue rather than definitive proof of FHH. Ignoring confounders or diagnostic overlap can deny useful surgery or cause an unnecessary operation.
Evaluation and Management of Primary Hyperparathyroidism: Fifth International Workshop, 2022
45.Which findings support surgery or continued surveillance in primary hyperparathyroidism?
Surgical criteria include calcium more than 1 mg/dL above the upper limit; vertebral fracture or qualifying T-score at or below −2.5; creatinine clearance or eGFR below 60 mL/min; stones or nephrocalcinosis; urinary calcium above 250 mg/day in women or 300 mg/day in men; or age below 50. Any one supports surgery. If observing, assess calcium, vitamin D, and renal function annually and three-site DXA generally every 1–2 years as indicated. Reassess surgery after new complications or qualifying deterioration. Cinacalcet lowers calcium; antiresorptives improve bone density. Localization imaging plans surgery after diagnosis and treatment selection.
Apply it
A patient has modest calcium elevation but distal radius T-score −2.7. Recognize a skeletal surgical criterion rather than waiting for calcium to rise further.
Common pitfall: Negative localization does not exclude disease. Medical calcium control and skeletal protection are distinct goals and do not constitute surgical cure.
Evaluation and Management of Primary Hyperparathyroidism: Fifth International Workshop, 2022
46.How should hypocalcemia be localized and urgently treated?
Confirm low ionized or albumin-adjusted calcium and measure PTH, phosphate, magnesium, renal function, and 25-hydroxyvitamin D. Low or inappropriately normal PTH favors hypoparathyroidism; high phosphate strengthens that pattern. Severe magnesium deficiency can impair PTH secretion and action, making calcium replacement insufficient until magnesium is corrected. Tetany, seizures, or arrhythmia require urgent intravenous calcium gluconate with ECG monitoring. Hypoparathyroidism commonly requires oral calcium and active vitamin D with monitoring for hypercalcemia and renal complications. [Society for Endocrinology acute hypocalcemia guidance](https://pmc.ncbi.nlm.nih.gov/articles/PMC5314808/) and [intravenous calcium addendum](https://pmc.ncbi.nlm.nih.gov/articles/PMC8117371/).
Apply it
After thyroid surgery, carpopedal spasm, low calcium, high phosphate, and low PTH require prompt calcium treatment and assessment of magnesium.
Common pitfall: Reference-range PTH may be inappropriately low during hypocalcemia. Correct magnesium deficiency and monitor calcium during active-vitamin-D treatment.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
47.Which findings suggest a mineralization disorder rather than uncomplicated osteoporosis?
Bone pain, proximal weakness, fractures, elevated alkaline phosphatase, and persistent hypophosphatemia should trigger evaluation for osteomalacia. Measure phosphate, calcium, PTH, renal function, and 25-hydroxyvitamin D. With chronic hypophosphatemia, paired fasting serum and urine phosphate/creatinine allow assessment of renal phosphate handling; reduced TmP/GFR indicates inappropriate renal phosphate loss. FGF23 excess causes phosphate wasting and low or inappropriately normal calcitriol. Acquired disease raises concern for tumor-induced osteomalacia; childhood onset or family history suggests inherited disease. Correct vitamin D deficiency, but investigate persistent hypophosphatemia rather than assuming deficiency explains everything. [Global osteomalacia guidance](https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13593).
Apply it
An adult with progressive bone pain and fractures has low phosphate despite corrected vitamin D status. Assess renal phosphate wasting and FGF23 before treating the presentation as ordinary osteoporosis.
Common pitfall: Low bone density alone does not distinguish deficient mineralization from reduced bone mass. Low vitamin D can coexist with tumor-induced osteomalacia.
Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
48.When is a bisphosphonate holiday reasonable?
Bisphosphonates remain in bone and can retain antiresorptive effects after discontinuation. In postmenopausal osteoporosis, reassess fracture risk after three to five years of treatment; patients who remain at high risk generally continue therapy, whereas selected low-to-moderate-risk patients may take a monitored holiday. Reassessment timing depends on the agent and exposure. New fracture, meaningful bone loss, or increasing clinical risk can justify restarting earlier. A holiday is a risk-based decision rather than a universal requirement.
Apply it
After several years of bisphosphonate therapy, one patient has no fractures and improved risk while another sustains a vertebral fracture. Consider a monitored holiday only for the appropriately lower-risk patient rather than stopping both automatically.
Common pitfall: A fixed treatment anniversary does not determine safety of stopping. The bisphosphonate holiday concept also cannot be transferred to denosumab because their persistence differs.
Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources
49.Why does denosumab discontinuation require another treatment plan?
Denosumab suppresses bone resorption through RANKL inhibition, but its effect reverses when treatment is delayed or stopped. Rebound bone turnover can cause rapid bone loss and increased fracture risk, including vertebral fractures. Unlike bisphosphonates, it is not managed with an unprotected drug holiday. If discontinuation is necessary, arrange subsequent antiresorptive therapy or another appropriate strategy to preserve benefit. Anticipating interruptions is part of treatment selection and follow-up.
Apply it
A patient receiving denosumab wants to stop because bone density has improved. Explain the rebound risk and organize timely sequential therapy rather than allowing treatment to lapse without an alternative skeletal protection plan.
Common pitfall: Improved bone density does not make abrupt denosumab cessation safe. Applying a bisphosphonate-style holiday can expose the patient to a predictable period of increased bone turnover.
Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources
50.Why is antiresorptive treatment needed after an anabolic osteoporosis course?
Bone-forming treatments can be appropriate for selected postmenopausal patients at very high fracture risk, including those with severe or multiple vertebral fractures. Their gains are not necessarily maintained after the treatment course ends. Subsequent antiresorptive therapy helps preserve bone density and fracture protection. Treatment sequencing should therefore be planned before the anabolic course finishes. Agent selection also requires consideration of contraindications and individual risk, rather than assuming all anabolic options have identical safety profiles.
Apply it
A patient with multiple vertebral fractures is completing an anabolic treatment course. Arrange follow-on antiresorptive treatment instead of waiting for a future density decline before deciding how to maintain the skeletal gains.
Common pitfall: Completing the prescribed anabolic course is not the end of osteoporosis care. Without maintenance treatment, gains can be lost despite an initially strong bone-density response.
Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources
51.Which patients are at greatest risk of severe denosumab-associated hypocalcemia?
The FDA boxed warning identifies advanced CKD, especially dialysis, as a major risk setting; concomitant CKD-mineral and bone disorder further increases risk. Assess kidney function, calcium, and evidence of CKD-MBD before considering denosumab. In advanced CKD, involve a clinician experienced in CKD-MBD to assess treatment suitability, manage the bone disorder, correct hypocalcemia, and arrange appropriate calcium and activated-vitamin-D treatment. Monitor calcium closely after administration, particularly during the first 2–10 weeks, when severe events commonly occur. Denosumab's lack of renal clearance does not remove this mineral-metabolism risk.
Apply it
A dialysis patient with low calcium and suspected renal osteodystrophy is referred for denosumab. Obtain CKD-MBD expertise and correct the mineral disorder before deciding whether the drug's benefits outweigh its risks.
Common pitfall: Routine nutritional vitamin D alone may not address advanced CKD-MBD. Abruptly stopping existing denosumab without a fracture-prevention transition plan creates a separate rebound risk.
FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab) | FDA · Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources
Thyroid Disorders15%
52.How does destructive thyroiditis differ from increased thyroid hormone synthesis?
Destructive thyroiditis releases stored hormone from injured follicles, producing thyrotoxicosis without increased synthesis. Radioactive iodine uptake is typically low, whereas Graves disease usually has increased diffuse uptake when testing is appropriate. Antithyroid drugs inhibit synthesis and therefore do not address the principal mechanism of destructive thyroiditis. Beta blockade can relieve adrenergic symptoms. Establishing the mechanism matters because identical high free T4 and suppressed TSH results can require very different treatment strategies.
Apply it
A patient has suppressed TSH, elevated free T4, neck discomfort, and low thyroid uptake. Recognize a destructive process and treat symptoms appropriately rather than assuming that every biochemical thyrotoxicosis requires a synthesis-blocking drug.
Common pitfall: Thyrotoxicosis describes hormone excess, not its source. Treating the laboratory pattern without identifying the mechanism can lead to ineffective antithyroid medication and unnecessary adverse effects.
53.Which clinical patterns distinguish painful, painless, and postpartum thyroiditis?
Subacute thyroiditis commonly causes thyroid pain and tenderness, whereas painless and postpartum thyroiditis are usually painless destructive processes. Any may progress through a thyrotoxic phase, a hypothyroid phase, and recovery, although not every patient experiences every phase. Follow-up testing is necessary because treatment needs can change over time and some patients develop persistent hypothyroidism. Pain treatment is relevant to subacute disease; antithyroid synthesis blockers do not correct stored-hormone release.
Apply it
Several months after delivery, a patient develops palpitations followed later by fatigue and low thyroid hormone levels. Consider the changing phases of postpartum thyroiditis and reassess function rather than assuming the initial thyrotoxicosis must persist.
Common pitfall: One thyroid panel cannot establish the whole course of thyroiditis. Continuing treatment unchanged through a transition from hormone excess to deficiency can produce avoidable symptoms.
54.How is levothyroxine monitored in primary hypothyroidism?
With an intact pituitary axis, TSH usually guides levothyroxine replacement in primary hypothyroidism. Reassess TSH approximately four to six weeks after starting treatment or changing the dose: levothyroxine's long half-life requires this interval for steady state and the corresponding TSH response. Repeat at similar intervals during titration. Once the target is reached, reassess in four to six months and then generally annually, earlier with relevant clinical or medication changes. Review adherence, administration, and interactions when results remain abnormal. [ATA thyroid hormone replacement guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC4267409/).
Apply it
After changing a levothyroxine dose, arrange TSH testing in four to six weeks rather than repeatedly adjusting treatment from results obtained only days apart.
Common pitfall: TSH does not reliably guide replacement in central hypothyroidism; free T4 is used instead. Early testing can reflect the previous dose rather than the new steady state.
Thyroid Hormone Treatment — American Thyroid Association · Hormone Replacement in Hypopituitarism Guideline Resources
55.How should levothyroxine be separated from calcium and iron?
Calcium and iron reduce levothyroxine absorption when taken together. Separate levothyroxine from either supplement, including prenatal vitamins containing them, by at least four hours. Take levothyroxine consistently under the same fasting administration conditions. Before increasing a previously effective dose, review supplement timing, food, missed tablets, and other medications. Correcting an interaction changes the absorbed dose even when the tablet strength stays constant, so follow-up thyroid testing is needed after administration changes.
Apply it
A patient's TSH rises after starting calcium and iron with morning levothyroxine. Move the supplements at least four hours away, standardize levothyroxine administration, and reassess thyroid function before committing to a permanent dose increase.
Common pitfall: Increasing the dose without correcting the interaction can cause overtreatment once the supplements are stopped or rescheduled.
Thyroid Hormone Treatment — American Thyroid Association · Hypothyroidism in Pregnancy | American Thyroid Association
56.How should treated overt and preconception subclinical hypothyroidism be managed when pregnancy begins?
For treated overt hypothyroidism, an early levothyroxine increase of about 25% is usual, followed by testing and titration. Consider preconception TSH and dose: standardized increases more often cause overtreatment with TSH below 1.5 mU/L or doses above 100 micrograms/day. For treated preconception subclinical hypothyroidism, evidence does not support a routine 25% increase; use a smaller individualized increase, such as 12.5 micrograms/day, or testing-guided adjustment. Test every four weeks until midgestation, at least once near 30 weeks, and approximately six weeks postpartum. After delivery, overt disease generally returns to the preconception dose; reassess continuing treatment for subclinical disease. [2026 ATA guideline](https://journals.sagepub.com/doi/pdf/10.1177/10507256261445624?download=true).
Apply it
A positive pregnancy test prompts review of the original diagnosis, recent TSH, and current dose before selecting the increase and arranging monitoring.
Common pitfall: Two extra weekly tablets can overtreat some patients. A normal preconception TSH does not remove the need for pregnancy monitoring.
57.When does a thyroid nodule need functional imaging?
Serum TSH helps determine whether a thyroid nodule needs radionuclide evaluation. When TSH is low, a scan can identify whether the nodule is autonomously functioning. Functional imaging answers a different question from ultrasound, which assesses structural characteristics and cervical nodes. A corresponding hyperfunctioning nodule is usually low risk for malignancy and generally does not require routine biopsy, but other nodules still need assessment. Radionuclide testing is inappropriate during pregnancy.
Apply it
An adult has a thyroid nodule and suppressed TSH. Obtain functional assessment when appropriate before choosing biopsy based solely on size, while using ultrasound to evaluate the nodule and any additional structural abnormalities.
Common pitfall: Ultrasound cannot establish hormone autonomy, and a scan does not replace structural assessment. A hot nodule also does not automatically classify every other thyroid lesion.
58.Which ATA ultrasound patterns determine thyroid nodule biopsy thresholds?
ATA Recommendation 8 and Table 6 use the complete sonographic pattern. High-suspicion solid hypoechoic nodules with features such as irregular margins, microcalcifications, or taller-than-wide shape generally warrant FNA at 1 cm. Intermediate-suspicion hypoechoic solid nodules also use a 1-cm threshold. Low-suspicion isoechoic or hyperechoic solid nodules generally use 1.5 cm. For very-low-suspicion spongiform nodules, consider FNA at 2 cm; observation is reasonable. Pure cysts need no diagnostic FNA, though drainage may relieve symptoms. Ultrasound selects lesions for sampling; cytology supplies cellular information.
Apply it
A 1.2-cm solid hypoechoic nodule with microcalcifications meets the ATA biopsy threshold, whereas a larger purely cystic lesion does not require diagnostic sampling.
Common pitfall: Size alone does not determine sampling. Do not mix ATA thresholds with another risk system without identifying which system governs the decision.
59.How does differentiated thyroid cancer risk determine surgery and radioactive iodine treatment?
Under 2025 ATA Recommendation 15, when surgery is chosen for differentiated thyroid cancer at most 2 cm without gross extrathyroidal extension or metastases, lobectomy is recommended unless bilateral cancer or another indication requires contralateral removal. Tumors larger than 4 cm, gross invasion, or clinically apparent nodal or distant metastases generally support total thyroidectomy with appropriate removal of involved disease. Recommendation 32 does not recommend routine radioactive iodine after total thyroidectomy for ATA low-risk disease; it recommends treatment for high-risk disease and consideration for intermediate-risk disease according to postoperative findings.
Apply it
A unilateral 1.6-cm intrathyroidal papillary cancer without metastases can be treated with lobectomy when surgery is selected; total thyroidectomy and radioactive iodine are not automatic requirements.
Common pitfall: Normal TSH does not exclude cancer or determine its treatment. The lobectomy pathway for low-risk differentiated cancer should not be extrapolated to other thyroid cancer histologies.
60.How should benign and nondiagnostic thyroid cytology lead to different follow-up?
Benign cytology generally supports observation with follow-up informed by ultrasound features and clinical changes. A nondiagnostic sample means too little suitable cellular material was obtained; it is not equivalent to a benign result and often requires repeat ultrasound-guided sampling. Reassess concerning growth, symptoms, or discordance between ultrasound and cytology. The goal is to avoid unnecessary surgery for reassuring lesions while ensuring that inadequate sampling or evolving risk does not become false reassurance.
Apply it
A thyroid aspirate contains insufficient follicular cells from a suspicious lesion. Arrange an appropriate repeat sampling strategy rather than placing the patient into the same routine observation pathway used after a satisfactory benign cytology result.
Common pitfall: Nondiagnostic means unanswered, not nonmalignant. Conversely, a satisfactory benign result does not automatically require surgery merely because the nodule remains visible on subsequent ultrasound.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give diabetes the largest share of study time, linking classification and diagnostic criteria to retinal, kidney, and foot complications, medication safety, pregnancy, inpatient decisions, and both diabetes-related and independent hypoglycemia.
- Interpret feedback relationships before memorizing reference intervals: calcium–PTH, cortisol–ACTH, testosterone–LH/FSH, estradiol–FSH, and free T4–TSH.
- Separate biochemical diagnosis, anatomical imaging, functional localization, and treatment eligibility in adrenal, parathyroid, pituitary, and thyroid disease.
- Use discriminating findings to evaluate hyperprolactinemia, gynecomastia, and suspected mineralization disorders rather than attributing every presentation to hormone deficiency or osteoporosis.
- Practise treatment transitions: steroid tapering, interruption of pump insulin, denosumab discontinuation, anabolic-to-antiresorptive therapy, and diagnosis-specific thyroid replacement changes during pregnancy.
- Use the expanded official outline to identify topics beyond this selective guide, including additional adrenal masses, pituitary tumors, reproductive disorders, rare bone diseases, and imaging procedures.
- Include food access, medication affordability, health literacy, and caregiver capability when selecting feasible endocrine treatment and rescue plans.
A practical preparation plan
1. Map the official scope
Read the January 2026 CERT outline and mark every subsection as secure, uncertain, or unfamiliar. Allocate approximately 24% of review to diabetes, 15% each to calcium/bone and thyroid, 12% to lipids/obesity/nutrition, 10% each to adrenal and pituitary, and 7% each to female and male reproduction.
2. Build physiological decision pathways
For each concept, identify the hormone source, feedback signal, expected compensatory response, and finding that would change management. Draw pathways for hypercalcemia, hypocalcemia, amenorrhea, low testosterone, hyperprolactinemia, gynecomastia, low free T4, polyuria, hypophosphatemia, and hypoglycemia without diabetes.
3. Practise laboratory interpretation and calculations
Calculate a calcium-to-creatinine clearance ratio with compatible units. Resolve discordant diabetes tests, identify inappropriate normal hormone values, apply pregnancy glucose thresholds, and distinguish medication or binding effects from true endocrine disease.
4. Work the questions before reading explanations
Choose one answer and state the decisive cue aloud. Review why each competing option fails, then record the missed distinction as a specific rule rather than copying the whole explanation.
5. Revisit safety and transitions
Use spaced flashcard review for adrenal crisis, fertility precautions, severe hypoglycemia, pump eligibility, steroid-related insulin changes, and osteoporosis sequencing. Include the practical steps a patient or caregiver must be able to perform.
6. Close gaps against the full outline
Return to the official expanded outline after completing the guide. Add unsampled topics and practise the listed imaging and procedure interpretations. Use performance on these drills to identify learning needs, without treating a small practice-set score as a pass prediction.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABIM Blueprints
- Endocrinology, Diabetes, and Metabolism Blueprint — Certification Examination (CERT), January 2026
- ABIM Endocrinology, Diabetes, and Metabolism Certification Policies
- Primary Adrenal Insufficiency Guideline Resources
- Primary Aldosteronism — Endocrine Society, July 2025
- Hormone Replacement in Hypopituitarism Guideline Resources
- Acromegaly — Endocrine Society Guideline Resources
- Lipid Management Guideline — Endocrine Society
- Pharmacological Management of Obesity Guideline Resources
- Hypothalamic Amenorrhea Guideline Resources
- Recommendations from the 2023 International Evidence-based Guideline for Polycystic Ovary Syndrome
- Testosterone Therapy for Hypogonadism Guideline Resources
- Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
- What Are My Options for Type 2 Diabetes Medications? — ADA
- High Risk for Hypoglycemia Guideline Resources
- Inpatient Hyperglycemia Guideline Resources
- Evaluation and Management of Primary Hyperparathyroidism: Fifth International Workshop, 2022
- Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources
- Thyroiditis — American Thyroid Association
- Thyroid Hormone Treatment — American Thyroid Association
- Thyroid Nodules — American Thyroid Association
- Consensus on criteria for acromegaly diagnosis and remission - PMC
- 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 - PMC
- 204629s040lbl.pdf
- FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab) | FDA
- Hypothyroidism in Pregnancy | American Thyroid Association
- Diagnosis of Cushing’s Syndrome Guideline Resources | Endocrine Society
- Male%20Infertility%20Unabridged%20Final.pdf
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 - PMC
- J%20of%20Bone%20%20%20Mineral%20Res%20-%202022%20-%20Bilezikian%20-%20Evaluation%20and%20Management%20of%20Primary%20Hyperparathyroidism%20%20Summary%20Statement.pdf
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer - PMC
- DTCGuidelines.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.